Development of Personalised Medicine within Hospitals: Myth or Reality? journal article Inesa Fausch Zeitschrift für Stoffrecht, Volume 18 (2021), Issue 2, Page 48 - 55 Personalised medicine has become one of the major focal points in global healthcare discourse. Due to its complexity, the use of autologous human materials as well as the need for a variety of specialists, its development and manufacturing has also become an issue of rising interest for hospitals. A comparative analysis on a number of countries in and outside Europe, that looks into legal systems allowing personalised therapies to be manufactured in hospitals, reveals that some countries, such as Russia, are characterised by a strategic approach only, while others, such as Spain or Great Britain, are willing to implement suitable legal instruments and are already developing personalised medicine on site in a non-routine manner. The recent examples of personalised CAR-T cell therapies demonstrate that this can be highly successful – so despite the diversity one can see across different jurisdictions and disparate legal rules on the regulation of medicinal products, hospitals have a central role to play in the production of personalised medical therapies in the future.
Geplante und bestehende Regulierungen in Bezug auf primäres und sekundäres Mikroplastik Vanessa Homann, Gregor Franßen